Crizotinib Capsules Suppliers & Bulk Manufacturers
Available Forms: Oral Capsules
Available Strengths: 200 mg, 250 mg
Reference Brands: Xalkori® (US & EU)
Category: Oncology Cancer Care
Crizotinib Capsules is available in Oral Capsules and strengths such as 200 mg, 250 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Crizotinib Capsules is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Crizotinib Capsules can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Crizotinib Capsules are a targeted therapy used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive cancers, as well as anaplastic large cell lymphoma (ALCL). As a tyrosine kinase inhibitor (TKI), Crizotinib blocks the activity of abnormal proteins responsible for cancer cell growth. Marketed under Xalkori®, Crizotinib is available in 200 mg and 250 mg oral capsule strengths. Manufactured under GMP-compliant conditions, it offers a reliable solution for pharmaceutical distributors targeting US and EU oncology markets, providing effective treatment options for precision cancer medicine.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
